---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053928"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:22:31.539478+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics Q1 net loss $98.7M; BEAM-101 expansion cohort opened, cash $1.1B into 2027

## Summary
- Net loss of $98.7M ($1.21 per share) vs $96.5M ($1.33 per share) in Q1 2023.
- Cash, cash equivalents and marketable securities $1.1B as of March 31, 2024; runway into 2027.
- R&D expenses $84.8M, G&A expenses $26.7M for Q1 2024.
- BEAM-101 BEACON trial sentinel cohort dosing completed; expansion cohort initiated with up to 45 patients.
- BEAM-302 CTA cleared in UK for Phase 1/2 in AATD; BEAM-301 IND submission on track for H1 2024.

## SEC filing metadata
- accession: 0000950170-24-053928
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017024053928/0000950170-24-053928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017024053928/beam-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053928
- JSON: https://secwatch.observer/filing/0000950170-24-053928.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053928.txt

## Key facts
- Earnings Releases
  Beam Therapeutics Inc. reported first quarter 2024 results: net income ($98.7 million), EPS ($1.21).
  - Period: first quarter 2024
  - Net income: ($98.7 million)
  - EPS: ($1.21)
  - Result: reported results
  source text: Net loss was $98.7 million for the first quarter of 2024, or $1.21 per share, compared to $96.5 million for the first quarter of 2023, or $1.33 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017024053928/0000950170-24-053928-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.